Answers are grounded in this paper and cite their sources.
Decitabine administered in 6-week cycles is active in older patients with higher-risk MDS, resulting in improvements of OS and AMLFS (nonsignificant), of PFS and AML transformation (significant), and of QOL. Short MDS duration was an independent adverse prognosticator.
No takes yet. Share an insight, caveat, or question.
Lübbert et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: